Immuneering Corporation (IMRX) Operating cash flow 2020–2025
Immuneering Corporation (IMRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$45.3MFY2025 · since FY2020: -$14.6M → -$45.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$45.3M | +17.6% |
| FY2024 | -$55.0M | -12.3% |
| FY2023 | -$49.0M | -11.0% |
| FY2022 | -$44.1M | -42.9% |
| FY2021 | -$30.9M | -111.0% |
| FY2020 | -$14.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IMRX financial trends
IMRX RevenueIMRX Net incomeIMRX Net marginIMRX Gross profitIMRX Gross marginIMRX Operating incomeIMRX Operating marginIMRX Free cash flowIMRX Capital expendituresIMRX Return on equityIMRX Stock buybacksIMRX Dividends paidIMRX Total assetsIMRX Total liabilitiesIMRX Shareholders’ equityIMRX overview →